SWOG clinical trial number
S0027

Phase II Trial of Sequential Vinorelbine and Docetaxel in Advanced Non-Small Cell Lung Cancer Patients Age Seventy and Older, or with Performance Status 2

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Vinorel/Doc/Adv NSCLC/Age >=70 PS 0-1/PS 2 any age; Selected IIIB & IV
Activated
09/01/2001
Closed
07/01/2003
Participants
NCORP, Members, Medical Oncologists

Research committees

Lung Cancer

Treatment

Docetaxel Vinorelbine tartrate

Eligibility Criteria Expand/Collapse

Pts. must have hist. or cyto. proven, newly diagnosed selected Stage IIIB or IV, primary NSCLC (adenocarcinoma, large cell carcinoma, squamous cell carcinoma or unspecified) or recurrent dz after surgery or RT; pts. must not have BAC or Stage IIIB tumor involving superior sulcus (Pancoast Tumor); pts. must have meas. or non-meas. dz; pts. must be either >= 70 yrs. of age w/PS 0-1 or PS 2 and any age; pts. must not have brain mets or >= Grade 2 symptomatic sensory neuropathy; meas. or non-meas. dz must be present outside the previous radiation field or area of resection, or a new lesion must be present; pts. must not have a history of hypersensitivity to docetaxel or other drugs formulated with polysorbate 80; pts. at the following 8 institutions ONLY: City of Hope, UC Davis, USC, UT San Antonio, Wayne State, Univ. of Colorado, PSOC/Univ. of Washington and Univ. of Kansas are strongly encouraged to have blood specimens collected and submitted.

CANCER CONTROL CREDIT: 0.5
TREATMENT CREDIT: 0.5

Publication Information Expand/Collapse

2021

The Association of Patient Fatigue and Outcomes in Advanced Cancer: An Analysis of Four SWOG Treatment Trials

J Mo;A Darke;K Guthrie;J Sloan;J Unger;D Hershman;M O'Rourke;M Bakitas;R Krouse JCO Oncology Practice, Aug;17(8):e1246-e1257; Jul 13;OP2001096. doi: 10.1200/OP.20.01096. Online ahead of print.

PMid: PMID34255538 | PMC number: PMC8360454

Association between Health-Related Quality of Life and Progression Free Survival in Patients with Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials

J Mo;A Darke;K Guthrie;I Subbiah;J Unger;D Hershman;R Krouse;M Bakitas;M O'Rourke JCO Oncology Practice, Apr;18(4):e442-e451

PMid: PMID34606328 | PMC number: PMC8360454

2020

The Association of Patient Fatigue and Outcomes in Advanced Cancer: An Analysis of Four SWOG Treatment Trials

J Mo;A Darke;K Guthrie;J Sloan;J Unger;D Hershman;M O'Rourke;M Bakitas;R Krouse J Clin Oncol 38, 2020 (suppl 29; abstr 140); ASCO Quality Care Symposium (October 9-10, 2020, Virtual), Rapid Abstract Presentation

2019

Clinical prognostic model for older patients with advanced non-small cell lung cancer

AK Ganti;X Wang;T Stinchcombe;Y Wang;J Bradley;HJ Cohen;K Kelly;R Paulus;SS Ramalingam;EE Vokes;H Pang Journal of Geriatric Oncology Feb 20. pii: S1879-4068(18)30197-8. doi: 10.1016/j.jgo.2019.02.007. [Epub ahead of print]

PMid: PMID30797707

2016

Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials

D Hershman;C Till;J Wright;D Awad;S Ramsey;W Barlow;L Minasian;J Unger Journal of Clinical Oncology Sep 1;34(25):3014-3022; 2016 Jun 20 [Epub ahead of print]

PMid: PMID27325863 | PMC number: PMC5012713

Comorbidities and risk of chemotherapy induced peripheral neuropathy among participants in SWOG clinical trials

DL Hershman;C Till;JD Wright;D Awad;S Ramsey;W Barlow;L Minasian;J Unger Journal of Clinical Oncology 34, 2016 (suppl; abstr 10001); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral presentation

2015

The complimentary nature of patient reported outcomes (PROs) and adverse event reporting in cooperative group oncology clinical trials: a pooled analysis (NCCTG N0591/Alliance)

PJ Atherton;DW Watkins-Bruner;CC Gotay;CM Moinpour;DV Satele;K Winter;PL Schaefer;B Movsas;J Sloan Journal of Pain and Symptom Management Oct;50(4):470-479

PMid: PMID26031708 | PMC number: PMC4657556

2012

Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer

Y Qi;A Ziegler;S Hillman;M Redman;S Schild;D Gandara;A Adjei;S Mandrekar Cancer 118(21):5358-5365;

PMid: PMID22434489 | PMC number: PMC3481159

2007

Chemotherapy in patients >80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6 [PMID17545843]

PJ Hesketh;RC Lilenbaum;K Chansky;A Dowlati;P Graham;RA Chapman;JJ Crowley;DR Gandara Journal of Thoracic Oncology 2(6):494-498

2006

Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027)

PJ Hesketh;K Chansky;DHM Lau;JH Doroshow;CM Moinpour;RA Chapman;JW Goodwin;HM Gross;JJ Crowley;DR Gandara Journal of Thoracic Oncology 1(6):537-544

2004

Sequential vinorelbine (V) and docetaxel (D) in advanced non-small cell lung cancer (NSCLC) patients age > 70, or with performance status (PS) 2: a SWOG phase II trial (S0027)

PJ Hesketh;K Chansky;DH Lau;J Crowley;DR Gandara Proc of the American Society of Clinical Oncology 23:627 (#7056)

Other Clinical Trials

SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
A082002

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007

RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open